The anti-CD52 monoclonal antibody Alemtuzumab has shown significant clinical activity in patients with previously treated advanced MF/SS and constitutes a second-line option for patients with advanced disease, although with less efficacy in tumor-stage MF and large cell transformation types (29, 30). The gene discussed is CD52; the disease is mycosis fungoides.